ASH 2018 | bb21217 results: a next-generation anti-BCMA CAR-T for R/R MM

Nina Shah

Promising results have been seen with bb21217, a next-generation anti-BCMA CAR T-cell therapy for the treatment of relapsed/refractory multiple myeloma (MM). Here, Nina Shah, MD, of the University of California, San Francisco, CA, discusses the preliminary safety and efficacy data from the ongoing CRB-402 trial (NCT03274219), which was presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video